Citizens Financial Group Inc. RI Buys 120,089 Shares of Pfizer Inc. $PFE

01 May 2026, 04:37 by Teresa Graham · The Cerbat Gem

Citizens Financial Group Inc. RI grew its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 34.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 465,598 shares of the biopharmaceutical company’s stock after acquiring an additional 120,089 shares during the period. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $11,593,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Horizon Financial Services LLC raised its stake in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares during the last quarter. YANKCOM Partnership bought a new position in shares of Pfizer in the fourth quarter worth about $28,000. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer in the third quarter worth about $29,000. True Wealth Design LLC raised its stake in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the last quarter. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer in the second quarter worth about $32,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PFE shares. Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday. HSBC boosted their price target on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Bank of America dropped their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.74.

View Our Latest Report on PFE

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Late‑stage trial win for ELREXFIO (elranatamab): Pfizer reported Phase 3 MagnetisMM‑5 results showing a statistically significant improvement in progression‑free survival for relapsed/refractory multiple myeloma, strengthening ELREXFIO’s commercial potential in a high‑value oncology indication. Reuters: Pfizer’s blood cancer drug meets main goal in late-stage trial
Positive Sentiment: VYNDAMAX patent settlement extends US protection to 2031: Pfizer reached settlements with multiple generics makers that effectively push off generic entry for its tafamidis franchise, protecting an asset Reuters and industry reports estimate is worth several billion in annual sales. This preserves a key revenue stream. Yahoo Finance: Pfizer reaches settlement to extend VYNDAMAX patent protection
Positive Sentiment: FDA accepted sBLA for PADCEV (priority review): Pfizer and Astellas announced the US FDA accepted a supplemental Biologics License Application for PADCEV, advancing a potential label expansion that could add to oncology revenues if approved. InsiderMonkey: Pfizer Among Best Medical Stocks Under $30 to Invest In?
Neutral Sentiment: Q1 earnings preview and estimates: Analysts and services are focused on Pfizer’s May 5 Q1 report; consensus (Zacks) currently forecasts ~$13.8B in sales and $0.74 EPS, so results that deviate from these metrics could move the stock. Zacks: Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
Neutral Sentiment: Market positioning and product markets: Reports note Pfizer’s participation in growing OTC markets (e.g., dry‑eye drops) and ongoing analyst coverage that highlights mixed sentiment — positive for pipeline progress but cautious on near‑term growth. Yahoo Finance: $4+ Billion OTC Dry Eye Drops Market Analysis
Negative Sentiment: Competitive pressure from Alnylam’s Amvuttra: Alnylam’s strong Q1 beat and a near‑200% move for its heart‑disease drug underscore competitive dynamics in certain cardiometabolic portfolios — a reminder that product launches by peers can affect market share and sentiment in overlapping indications. Yahoo Finance: Alnylam surges after its Pfizer‑rivaling blockbuster jumps nearly 200%
Negative Sentiment: Minor analyst estimate tweaks: Erste Group made a very small FY2027 EPS trim, and some analysts express mixed views — not a large revision but a headwind if further downgrades occur ahead of earnings. (No link)

Pfizer Trading Up 1.8%

PFE opened at $26.75 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a market cap of $152.08 billion, a price-to-earnings ratio of 19.67 and a beta of 0.43. The firm has a 50 day simple moving average of $27.17 and a 200 day simple moving average of $26.09. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s payout ratio is currently 126.47%.

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.